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The BRCT domain from Rhp9 (a Schizosaccharomyces pombe DNA-
damage checkpoint protein) has been expressed, puri®ed and
crystallized. Overexpression in bacterial cells was achieved by
minimizing aeration during host cell growth. A robotic screen was
used to determine the solubility parameters; concentration of the
protein was achieved by exploiting this information. Single crystals
suitable for X-ray analysis were obtained in two forms by vapour
diffusion (trigonal, unit-cell parameters a = b = 228.04, c = 70.42 AÊ ,
and tetragonal, P4/m Laue group symmetry, unit-cell parameters
a = b = 72.3, c = 91.1 AÊ ).
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1. Introduction
Inherited mutations in the BRCA1 gene
predispose women to breast and ovarian
cancers. BRCA1 encodes a tumour suppressor,
BRCA1 (Miki et al., 1994), implicated in DNA
repair, cell-cycle checkpoint control and RNA
transcription (Deng & Brodie, 2000; Scully &
Livingston, 2000). The BRCA1 protein
comprises two distinct regions: an N-terminal
RING motif and a C-terminal BRCT (BRCA1
C-terminal) motif. The C-terminal motif
contains two copies of the approximately
90±100-residue sequence known as a BRCT
repeat (Koonin et al., 1996; Callebaut &
Mornon, 1997). The two repeats occur in
tandem with a short intervening sequence and
together this arrangement is termed a BRCT
domain. A BRCT superfamily comprising over
40 eukaryotic proteins containing the BRCT
repeat sequence has been described (Bork et
al., 1997; Huyton et al., 2000). BRCT repeat
sequences occur singly, multiply or in tandem
pairs as in a BRCT domain such as that of
BRCA1. No precise biological function is
known, although BRCT repeats are prevalent
in proteins concerned with DNA repair or cell-
cycle control. Both the budding yeast check-
point protein RAD9 and its homologue in
®ssion yeast Rhp9 have a BRCT domain
comprising a tandem pair of C-terminal BRCT
repeats. The Rhp9 (Crb2) gene was cloned by
complementation of the phenotype of the
MMS-sensitive mutant mms-64 (rhp-64)
(Willson et al., 1997). The mutation (C664S)
was located within the linker region between
the two C-terminal BRCT repeats (Ho, 2001).
Here, we describe the cloning, expression,
preparation and crystallization of this C-term-
inal region from Rhp9 as an initial step towards
the structural solution of the Rhp9 BRCT
domain (Rhp9_BRCT). In particular, we
explain how problems of low yield and poor
solubility were overcome in order to obtain
suf®cient quantities of the soluble concen-
trated Rhp9 domain for crystallography.
2. Materials and methods
2.1. Preparation of the Rhp9 BRCT domain
(Rhp9_BRCT)
The sequence encoding the BRCT domain
(BRCT 1+2 Rhp9) was ampli®ed by PCR from
S. pombe (primer 1, 50-AGAACCATGGA-
TACAGCTCATCTTTGACG-30; primer 2, 50-
AAACCGAATTCAAGTAGAAATATCAG-
ACTG-30) and inserted as an NcoI/EcoRI
fragment into the pRsetB expression vector
(Invitrogen). The polylinker region between
the His tag and the start of the gene was
excized using the ¯anking NheI and NcoI sites.
The Rhp9 BRCT domain was expressed
as a single soluble His-tagged polypeptide
(referred to here as Rhp9_BRCT) in Escher-
ichia coli FB810 (DE3) cells. Cells were
cultured overnight at 310 K on LB agar plates
supplemented with 100 mg mlÿ1 ampicillin.
Several fresh colonies were used to inoculate a
100 ml LB starter culture, also containing
ampicillin. The starter culture was incubated
overnight at 310 K with shaking and aeration.
A 1 l main culture of LB supplemented with
ampicillin and contained within a 2 l ¯ask (to
minimize aeration) was inoculated with 10 ml
of starter culture. The main culture was incu-
bated with shaking at 310 K until the cell
culture reached an optical density measured at
600 nm of between 0.6 and 0.8. Expression was
then induced by addition of IPTG to a ®nal
concentration of 0.1 mM and the incubation
temperature was reduced to 303 K. Incubation
was continued for a further 3±4 h, when cells
were harvested by centrifugation at 4000g for
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15 min. The cell pellet was resuspended in
30 ml of ice-cold buffer A (Tris±HCl pH 7,
500 mM NaCl plus `Complete' EDTA-free
protease-inhibitor cocktail from Boehringer
Mannheim) and stored at 193 K pending
further preparation. Cell pellets were
thawed and lysed by sonication on ice using
4  30 s bursts at full power with cooling
between bursts to complete disruption of the
cells. The lysate was clari®ed by centrifuga-
tion at 48 500g for 1 h, then loaded at
2 ml minÿ1 onto a Pharmacia XK16 column
containing 10 ml Ni±NTA resin (Qiagen)
previously equilibrated with buffer A. The
column was washed to a stable baseline with
buffer A and then washed for a further 10
column volumes using a step gradient of
95% buffer A and 5% buffer B (as buffer A
plus 1 M imidazole).
The bound protein was eluted in 10
column volumes of 30% buffer B and
collected in 5 ml fractions. Prior to elution,
25 ml aliquots of 1 M EDTA and 1 M DTT
plus 500 ml aliquots of 5 M NaCl were
dispensed into each collection tube, so that
the ®nal EDTA, DTT and NaCl concentra-
tions in each fraction collected were 5 mM,
5 mM and 1 M, respectively. Peak fractions
were identi®ed by SDS±PAGE, pooled and
stored at 277 K prior to size-exclusion
chromatography. Protein sample was loaded
in 5 ml aliquots onto a Superdex 75 column
(Vt ’ 100 ml) previously equilibrated in
buffer C (Tris±HCl pH 7, 1 M NaCl, 5 mM
EDTA, 5 mM DTT plus `Complete' EDTA-
free protease-inhibitors cocktail) and eluant
was collected in 2.5 ml fractions. Fractions
containing Rhp9_BRCT were identi®ed
by SDS±PAGE, pooled and the protein
concentration was estimated spectro-
photometrically. The sample was con®rmed
to be the Rhp9 BRCT domain protein by
means of mass spectrometry and N-terminal
analysis (data not shown). The protein was
stored at 277 K at a concentration of
approximately 1 mg mlÿ1 pending crystallo-
graphic analysis.
2.2. Automated solubility trial
An automated trial was devised to char-
acterize Rhp9_BRCT solubility using a
Douglas Instruments IMPAX (Chayen et al.,
1990, 1992, 1994) Crystallization Robot
(see http://www.douglas.co.uk/impax.htm)
and accompanying X-step Optimization
software. A pH gradient ranging between
5.84 and 8.67 was dispensed versus an NaCl
gradient ranging between 0 and 1 M. The pH
range was achieved using 500 mM NaH2PO4
pH 4.15 in line 3 and 500 mM Na2HPO4 pH
8.67 in line 4. Protein (Rhp9_BRCT protein
at 2.5 mg mlÿ1 in 20 mM sodium phosphate
buffer pH 8, 300 mM NaCl, 300 mM imida-
zole) was loaded in line 1, NaCl stock (5 M)
in line 2 and water (distilled, demineralized,
ultra-®ltered) in line 5. 3 ml drops were
dispensed into a Nunc HLA 72-well plate
containing approximately 12 ml of mineral
oil. Protein solubility was assessed by
microscopic examination of the drops for
signs of precipitation both immediately after
dispensing and following incubation at room
temperature overnight. Results from this
screen were used to determine the eventual
Rhp9_BRCT puri®cation and storage
buffers for optimal solubility and also in¯u-
enced the development of a concentration
protocol (see x3).
2.3. Rhp9_BRCT concentration.
Concentration was achieved by deliberate
precipitation using a low-salt buffer (20 mM
Tris pH 8 only) followed by dissolution of
the protein pellet in the desired volume
of optimal buffer (50 mM Tris pH 7, 1 M
NaCl). In this way, concentrations of up
to 20 mg mlÿ1 were achieved which were
suf®cient for crystallography. Concentrated
protein was clari®ed by centrifugation
followed by either 0.2 or 0.1 mm ultra®ltra-
tion in preparation for crystal trials. Analysis
by dynamic light scattering (data not shown)
ensured that it was not aggregated.
2.4. Crystallization and preliminary X-ray
analysis of Rhp9_BRCT
Sparse-matrix Crystal Screens 1 and 2
(Hampton Research; Jancarik & Kim, 1991;
Cudney et al., 1994) were reordered for
compatibility with Douglas Instruments
ASPRUN software. This involved organizing
the solutions into three sections: viscous
organic precipitants, non-viscous organic
precipitants and inorganic precipitants. The
solutions within each section were ordered
alphabetically by precipitant, by increasing
concentrations and by pH where a precipi-
tant was used more than once at the same
concentration. The salt precipitants were
ordered by anion followed by cation. Precise
details can be viewed at the websites http://
www.douglas.co.uk/cryscr1.htm and http://
www.douglas.co.uk/cryscr2.htm.
Solutions were dispensed and mixed in a
1:1 ratio with a 15 mg mlÿ1 solution of
Rhp9_BRCT in 50 mM Tris pH 7, 1 M NaCl
using the Douglas Instruments robot. Drops
were delivered into a Nunc HLA 72-well
plate (one screen per plate) containing
approximately 12 ml of mineral oil; the ®nal
volume of each drop was 2 ml. Duplicate
screens were set up at both room tempera-
ture and 287 K. Interesting conditions were
investigated further by microbatch using the
robot's X-step Optimization program and
also by vapour-diffusion experiments until
an optimum condition was established.
Excessive nucleation was eliminated by
ultra®ltration of the crystal buffer and
®ltration of the protein solution (Chayen et
al., 1993).
3. Results and discussion
3.1. Preparation of Rhp9_BRCT
A number of different E. coli strains were
screened as hosts during optimization of
Rhp9_BRCT expression (data not shown).
These small-scale (5 ml cultures) expression
trials revealed that yields were improved by
omitting the pLysS plasmid and by using
FB810 (DE3) cells in preference to other
strains. Initial attempts to scale up expres-
sion from 5 ml to 1 l resulted in a severe
reduction in Rhp9_BRCT expression levels.
Rhp9_BRCT was clearly visible on
Coomassie stained gels when prepared from
a 5 ml culture, yet Western blotting was
required to detect Rhp9_BRCT prepared
from a 1 l culture. In order to investigate the
effect of changes in aeration level on accu-
mulation of soluble Rhp9_BRCT, we
performed shake-¯ask cultures over a range
of media volumes (400±1000 ml) in identical
(2 l) ¯asks and under identical culture
conditions. Surprisingly, this indicated that
over the range of conditions tested, soluble
accumulation of Rhp9_BRCT was inversely
proportional to aeration level/agitation ef®-
ciency (Fig. 1). Higher aeration therefore
resulted in lower accumulation of soluble
Rhp9_BRCT. Soluble expression was
further improved by lowering the incubation
temperature to 303 K (from 310 K) during
Figure 1
Western blot demonstrating the effect of aeration on
Rhp9_BRCT expression. Values for culture volume
expressed as a percentage of total ¯ask volume were,
from left to right: 30, 40, 50, and 20% (control lane).
A value of 50% (e.g. 1 l in a 2 l ¯ask) was adopted for
large-scale growths.
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induction and by using a lower level of IPTG
(0.1 mM rather than 1 mM). Initially, the
lysis and IMAC puri®cation was attempted
in a buffer of 50 mM Tris pH 8, 100 mM
NaCl. However, Rhp9_BRCT did not
remain soluble in this buffer once its
concentration exceeded 1 mg mlÿ1 and
precipitation occurred immediately on
elution from the Ni±NTA column. To reduce
precipitation, a 50 mM phosphate buffer pH
8 containing 300 mM NaCl was used for the
IMAC step and fractions were collected in
tubes containing enough stock EDTA to
bring the ®nal concentration in each fraction
to 5 mM. This alleviated problems of
Rhp9_BRCT precipitation on elution, but
storage below room temperature still caused
precipitation. At concentrations of approxi-
mately 0.5 mg mlÿ1 a slight precipitate
could be observed and concentration
beyond 2.5 mg mlÿ1 could not be achieved
using conventional ultra®ltration methods.
Further puri®cation by size-exclusion chro-
matography was also hampered by the
tendency of Rhp9_BRCT to precipitate on
the column.
3.2. Automated solubility trial
At this stage, we devised a screen to
investigate Rhp9_BRCT solubility. This
used the Douglas Instruments robot to
dispense a grid of conditions ranging pH
against NaCl concentrations at room
temperature (Fig. 2). We used the maximum
concentration of Rhp9_BRCT then avail-
able (2.5 mg mlÿ1) in the buffer prevailing
following the ®rst successful IMAC step (i.e.
50 mM sodium phosphate pH 8, 300 mM
NaCl, 300 mM imidazole). The results
(Fig. 3) demonstrated that Rhp9_BRCT was
most soluble at pH 7.12, where it remained
in solution at 550 mM NaCl (plus 150 mM
®nal imidazole). As the NaCl concentration
increased, the Rhp9_BRCT solubility
improved and the range of pH tolerated
without precipitation widened. The
maximum pH range (pH 6.07±8.67) was
achieved at a minimum NaCl concentration
of 950 mM (plus 150 mM ®nal imidazole).
Following this screen, the buffers used
during puri®cation were modi®ed by
reverting to Tris (preferable to phosphate
for crystallography), reducing the pH to 7
and increasing the NaCl concentration used
to 500 mM during IMAC and 1 M during
size-exclusion chromatography. The routine
use of 5 mM EDTA and 5 mM DTT down-
stream of IMAC, plus `Complete' (EDTA-
free) protease-inhibitor cocktail and 0.01%
sodium azide throughout, also helped to
Figure 2
Automated solubility screen dispensed under oil by Douglas Instruments robot into a 72-well microtitre plate.
Protein stock concentration was 2.5 mg mlÿ1, the pH range was 5.84±8.67 and the NaCl concentration range was
0±996.5 mM. The NaCl stock concentration was 5 M. The ®nal protein concentration was 1.0 mg mlÿ1 and the
®nal buffer concentration was 50 mM.
Figure 3
Micrographs of Rhp9_BRCT crystals grown by
vapour diffusion under condition 1. Approximate
dimensions of the crystals are 15  15  800 mm.
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stabilize the protein during puri®cation and
storage at 277 K.
3.3. Rhp9_BRCT concentration
Even once optimum conditions for
Rhp9_BRCT solubility had been estab-
lished, the pure protein could not be
concentrated beyond 2.5 mg mlÿ1 by
conventional (i.e. ultra®ltration-based)
methods. Consequently, we exploited the
tendency of Rhp9_BRCT to precipitate in
low-salt solution and our ability to redis-
solve the precipitate in a high-salt solution.
This had the advantage of allowing us to
select a desired ®nal concentration simply by
precipitating a known volume of 1 mg mlÿ1
Rhp9_BRCT stock and then calculating the
required volume of the high-salt solution.
Centrifugation and ®ltration steps followed
dissolution to ensure that there were no
undissolved aggregations remaining in the
®nal solution which might adversely in¯u-
ence crystal trials, either by inducing
unwanted precipitates or by providing an
excessive number of nucleation sites. Protein
concentrated in this way was analysed by
means of dynamic light scattering,
con®rming that the solution was mono-
disperse and contained a 36 kDa monomeric
protein (data not shown).
3.4. Crystallization of Rhp9_BRCT
The sparse-matrix trials revealed two
potential conditions; when optimized, both
produced crystals suitable for X-ray studies.
In each case, the protein was prepared in a
solution of 50 mM Tris pH 7, 1 M NaCl.
3.4.1. Condition 1. Straw-like crystals
15  800 mm (Figs. 3a and 3b) grew at
room temperature in 1±2 d from hanging
drops consisting of 50% protein solution
(6 mg mlÿ1) and 50% well buffer. Well
buffer comprised 100 mM sodium cacody-
late pH 6.5, 7.26% PEG 8000 and 200 mM
calcium acetate. Crystals diffracted to 4 AÊ
and were found to be in a trigonal space
group, most likely P3221, with approxi-
mately six molecules per asymmetric unit
and a solvent content of 60%. Unit-cell
parameters were a = b = 228.04, c = 70.42 AÊ ,
 =  = 90,  = 120.
3.4.2. Condition 2. Small crystals 50 mm
across were grown (not shown) in hanging
drops at 287 K using a well solution
consisting of 100 mM Tris±HCl pH 8.5, 2.0 M
ammonium sulfate and 7 mg mlÿ1 protein
solution. Data were collected to 5 AÊ and the
crystals were found to be tetragonal, prob-
ably with P4/m Laue group symmetry, and
had unit-cell parameters a = b = 72.3,
c = 91.1 AÊ and one molecule per asymmetric
unit. The solvent content was calculated to
be 70%.
4. Summary
Here, we have described the preparation
and crystallization of the Rhp9 BRCT
domain. In doing so we have drawn atten-
tion to the fact that reduced levels of protein
expression may occasionally arise owing to
aeration levels which are too high, rather
than too low as might intuitively be
expected. We have also demonstrated a
screen to establish the solubility character-
istics of a protein, enabling the optimization
of buffer conditions during protein puri®-
cation.
This work was supported by Cancer
Research UK.
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